ClinicalTrials.gg
CompletedNCT01124838Visual IIUpdated Jul 7, 2021Results posted

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

A Phase 3 interventional study of Adalimumab and Prednisone in Uveitis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing adalimumab in Uveitis — 3 open to participants now, 3 under way, 1 of them phase 3. Adalimumab · Uveitis.

Enrollment
3rd of 14
261 · median 87
Started
2010
with 2 others
Phase 3
5 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
2 of 14
AbbVie (prior sponsor, Abbott)

Among the 14 studies testing adalimumab in Uveitis, this one is the 3rd largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 3, and was the 4th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

3 of the 14 studies testing adalimumab in Uveitis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing adalimumab in Uveitis, or all of them as a file.
02

Study summary

A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

03

Conditions studied

  • Uveitis

Browse trials for

Keywords

  • Uveitis
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is diagnosed with non-infectious intermediate, posterior, or panuveitis.
  • Subject that for ≥ 28 days prior to the Baseline visit has inactive disease and is taking ≥ 10 mg of oral prednisone to maintain this inactive state and fulfillment of all 3 of the following criteria based on the Investigator's clinical judgment at the Screening and Baseline visits for both eyes:

    • Subject without active, inflammatory chorioretinal and/or inflammatory retinal vascular lesions.
    • Subject with anterior chamber cell grade ≤ 0.5+ according to Standardization of Uveitis Nomenclature (SUN) criteria.
    • Subject with vitreous haze grade ≤ 0.5+ according to National Eye Institute (NEI)/SUN criteria.
  • Subject is on oral prednisone 10 to 35 mg/day (or oral equivalent) at Baseline and the dose has not been increased in the past 28 days or decreased in the past 14 days.
  • Subject must have a documented history of experiencing at least one disease flare within 18 months of the Screening visit. This flare has to occur during or up to a maximum of 28 days after tapering off the oral corticosteroid therapy.
  • Subjects who do not have previous, active or latent tuberculosis (TB). Only one TB test is required to allow the subject in the study. Subjects with either negative purified protein derivative (PPD) (\< 5 mm of induration) or negative QuantiFERON®-TB Gold test (or interferon-gamma release assay (IGRA) equivalent) are eligible. Subjects with a repeat indeterminate QuantiFERON®-TB Gold test (or IGRA equivalent) result are not eligible. Note, that only one TB screening test is allowed and required. A repeat QuantiFERON®-TB Gold test (or IGRA equivalent) is not permitted if the PPD skin test is positive. The TB screening tests are diagnostic tests. In the event of a negative TB screening test, the results are to be interpreted in the context of the patient's epidemiology, history, exam findings, etc. and it is the responsibility of the investigator to determine if a patient has previous, active or latent tuberculosis or not. Under no circumstances can a patient with a positive PPD result or positive QuantiFERON®-TB Gold test (or IGRA equivalent) enter the study.

Exclusion criteria

Exclusion Criteria:

  • Subject with isolated anterior uveitis.
  • Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Lyme disease, toxoplasmosis, human T-lymphotropic virus type 1 (HTLV-1) infection, Whipple's disease, herpes zoster virus (HZV) and herpes simplex virus (HSV).
  • Subject with serpiginous choroidopathy.
  • Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.
  • Subject with intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury.
  • Subject with best corrected visual acuity (BCVA) less than 20 letters (ETDRS [Early Treatment Diabetic Retinopathy Study]) in at least one eye at the Baseline visit.
  • Subject with intermediate uveitis or panuveitis that has signs of intermediate uveitis (e.g. presence or history of snowbanking or snowballs) and symptoms and/or magnetic resonance imaging (MRI) findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis or panuveitis that have signs of intermediate uveitis (e.g. presence or history of snowbanking or snowballs) must have a brain MRI within 90 days prior to the Baseline visit.
  • Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy (except intravitreal anti- vascular endothelial growth factor (VEGF) therapy) with a potential therapeutic impact on non-infectious uveitis.
  • Subject on concomitant therapy other than methotrexate, cyclosporine, mycophenolate mofetil or an equivalent drug to mycophenolate mofetil (e.g., mycophenolic acid), azathioprine or tacrolimus within 28 days of Baseline or has discontinued an immunosuppressive therapy including methotrexate, cyclosporine, mycophenolate mofetil or an equivalent drug to mycophenolate mofetil (e.g., mycophenolic acid), azathioprine or tacrolimus within 28 days of Baseline.
  • If entering the study on one concomitant immunosuppressive therapy, dose has not been stable for at least 28 days prior to the Baseline visit or is not within the following allowable doses at the Baseline visit:

    • Methotrexate (MTX) ≤ 25 mg per week
    • Cyclosporine ≤ 4 mg/kg per day
    • Mycophenolate mofetil ≤ 2 grams per day or an equivalent drug to mycophenolate mofetil (e.g. mycophenolic acid) at an equivalent dose approved by the Medical Monitor
    • Azathioprine ≤ 175 mg per day
    • Tacrolimus (oral formulation) ≤ 8 mg per day
  • Subject has Retisert® (glucocorticosteroids implant) within 3 years prior to the Baseline visit or has had complications related to the device. Subject has had Retisert® (glucocorticosteroid implant) removed within 90 days prior to the Baseline visit or has had complications related to removal of the device.
  • Subject has received intraocular or periocular within 90 days prior to the Baseline visit.
  • Subject with proliferative or severe non-proliferative diabetic retinopathy or macular edema due to diabetic retinopathy.
  • Subject with neovascular/wet age-related macular degeneration.
  • Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.
  • Subject with cystoid macular edema unless the retinal changes are persistent, residual and stable as defined by the SUN criteria (persistent is > 3 months duration).
  • Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.
  • Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit.
  • Subject has received intravitreal anti-VEGF therapy:

    • within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab);
    • or within 60 days of the Baseline visit for anti-VEGF Trap (Aflibercept).
  • Subject on systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit.
  • Subject with a history of scleritis.
  • Subject on cyclophosphamide within 30 days prior to the Baseline visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.

    Drug: Prednisone · Drug: Placebo

  • Experimental
    Adalimumab

    Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.

    Drug: Adalimumab · Drug: Prednisone

Interventions

  • Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.

    Also known as: ABT-D2E7, Humira

  • Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Time to Treatment Failure on or After Week 2

    Treatment failure was defined by the occurrence of a uveitis flare (the inability to maintain disease control). To be considered treatment failure, ≥ 1 of these criteria had to be present in at least 1 eye at Week 2 or all other visits: * New active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesions relative to Baseline * 2-step increase relative to Baseline in anterior chamber cell grade or vitreous haze grade * Worsening of best corrected visual acuity by ≥ 15 letters relative to baseline. Time to treatment failure was analyzed using the Kaplan-Meier method. Dropouts for reasons other than treatment failure at any time during the study were censored at the drop out date. Per protocol, the primary analysis was performed in the Main Study population which included all randomized participants recruited outside Japan; for completeness results are also reported below for the Integrated dataset which includes participants recruited in Japan.

    Time frame: From Baseline until end of study (up to 80 weeks)

Secondary outcomes

  1. Change in Anterior Chamber (AC) Cell Grade in Each Eye From Baseline to the Final/Early Termination Visit

    Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = \< 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = \> 50 cells.

    Time frame: Baseline and at the Final/Early Termination Visit (up to 80 weeks)

  2. Change in Vitreous Haze (VH) Grade in Each Eye From Baseline to the Final/Early Termination Visit

    Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.

    Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)

  3. Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit

    Using corrective lenses based on that visit's refraction testing, participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart. On the logMAR scale, 0 is equivalent to 20/20 visual acuity, the range of normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.

    Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)

  4. Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2

    Optical coherence tomography was performed at every visit using 1 of 3 approved machines. Images were evaluated by a central reader. Macular edema was defined as cystoid macular edema. OCT evidence of macular edema on or after Week 2 was to be counted as an event. Dropouts due to reasons other than OCT evidence of macular edema were to be considered as censored observations at the time of dropping out.

    Time frame: From Baseline until the Final Visit (up to 80 weeks)

  5. Percent Change in Central Retinal Thickness in Each Eye From Baseline to the Final/Early Termination Visit.

    Central retinal thickness was measured using OCT and assessed by a central reader.

    Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)

  6. Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit

    The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

    Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)

  7. Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit

    The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 distance vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

    Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)

  8. Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit

    The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The near vision subscore is calculated from the answers to 3 near vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

    Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)

  9. Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit

    The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The ocular pain subscore is calculated form the answers to 2 eye pain questions and ranges from 0 to 100, where higher scores or increases in score indicate less pain.

    Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)

07

Results

Posted Jun 21, 2016

Participant flow

This study includes a Japan sub-study. A total of 261 adults with inactive non-infectious intermediate uveitis, posterior uveitis or panuveitis were randomized at 72 study sites worldwide; 229 participants at 62 study sites in Australia, Israel, Latin America, North America, and Europe (Main Study), and 32 participants at 10 study sites in Japan.

Participant flow — Overall Study
MilestonePlaceboAdalimumab
Started130131
Enrolled in main study114115
Enrolled in japan sub-study1616
Completed112116
Not completed1815
Withdrew: Miscellaneous42
Withdrew: Adverse event711
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up20

Outcome measures

PrimaryTime to Treatment Failure on or After Week 2

Treatment failure was defined by the occurrence of a uveitis flare (the inability to maintain disease control). To be considered treatment failure, ≥ 1 of these criteria had to be present in at least 1 eye at Week 2 or all other visits: * New active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesions relative to Baseline * 2-step increase relative to Baseline in anterior chamber cell grade or vitreous haze grade * Worsening of best corrected visual acuity by ≥ 15 letters relative to baseline. Time to treatment failure was analyzed using the Kaplan-Meier method. Dropouts for reasons other than treatment failure at any time during the study were censored at the drop out date. Per protocol, the primary analysis was performed in the Main Study population which included all randomized participants recruited outside Japan; for completeness results are also reported below for the Integrated dataset which includes participants recruited in Japan.

Time frame:
From Baseline until end of study (up to 80 weeks)
Reported as:
Median · months
Time to Treatment Failure on or After Week 2
monthsMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Time to Treatment Failure on or After Week 28.3 (3.0 to NA)NA (4.7 to NA)5.6 (2.6 to NA)NA (3.9 to NA)
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · Log Rank · p = 0.004 · Hazard ratio (hr): 0.57 · 95% CI 0.39 to 0.84
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · Log Rank · p = <0.001 · Hazard ratio (hr): 0.52 · 95% CI 0.37 to 0.74
SecondaryChange in Anterior Chamber (AC) Cell Grade in Each Eye From Baseline to the Final/Early Termination Visit

Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = \< 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = \> 50 cells.

Time frame:
Baseline and at the Final/Early Termination Visit (up to 80 weeks)
Reported as:
Mean · units on a scale
Change in Anterior Chamber (AC) Cell Grade in Each Eye From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Left eye0.57 ± 1.0010.41 ± 0.9690.61 ± 1.0050.46 ± 0.996
Right eye0.53 ± 0.9630.40 ± 0.9270.60 ± 0.9920.44 ± 0.950
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.218 · Mean difference: -0.14 · 95% CI -0.37 to 0.08The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.164 · Mean difference: -0.15 · 95% CI -0.36 to 0.06The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
SecondaryChange in Vitreous Haze (VH) Grade in Each Eye From Baseline to the Final/Early Termination Visit

Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.

Time frame:
Baseline and Final/Early Termination Visit (up to 80 weeks)
Reported as:
Mean · units on a scale
Change in Vitreous Haze (VH) Grade in Each Eye From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Left eye0.33 ± 0.7330.16 ± 0.6010.35 ± 0.7490.18 ± 0.614
Right eye0.27 ± 0.6050.18 ± 0.6040.36 ± 0.7290.18 ± 0.602
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.070 · Mean difference: -0.13 · 95% CI -0.28 to 0.01The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.016 · Mean difference: -0.17 · 95% CI -0.31 to -0.03The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
SecondaryChange In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit

Using corrective lenses based on that visit's refraction testing, participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart. On the logMAR scale, 0 is equivalent to 20/20 visual acuity, the range of normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.

Time frame:
Baseline and Final/Early Termination Visit (up to 80 weeks)
Reported as:
Mean · logMAR
Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit
logMARMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Left eye0.06 ± 0.2390.01 ± 0.2510.07 ± 0.2300.02 ± 0.241
Right eye0.02 ± 0.198-0.01 ± 0.1650.04 ± 0.2160.00 ± 0.169
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.096 · Mean difference: -0.04 · 95% CI -0.08 to 0.01The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.044 · Mean difference: -0.04 · 95% CI -0.09 to 0.00The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
SecondaryTime to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2

Optical coherence tomography was performed at every visit using 1 of 3 approved machines. Images were evaluated by a central reader. Macular edema was defined as cystoid macular edema. OCT evidence of macular edema on or after Week 2 was to be counted as an event. Dropouts due to reasons other than OCT evidence of macular edema were to be considered as censored observations at the time of dropping out.

Time frame:
From Baseline until the Final Visit (up to 80 weeks)
Reported as:
Median · months
Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2
monthsMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · Log Rank · p = 0.491 · Hazard ratio (hr): 0.75 · 95% CI 0.34 to 1.69The hazard ratio of adalimumab versus placebo was calculated using proportional hazards regression with treatment as factor.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · Log Rank · p = 0.185 · Hazard ratio (hr): 0.60 · 95% CI 0.28 to 1.28The hazard ratio of adalimumab versus placebo was calculated using proportional hazards regression with treatment and race (Japanese versus non-Japanese) as factors.
SecondaryPercent Change in Central Retinal Thickness in Each Eye From Baseline to the Final/Early Termination Visit.

Central retinal thickness was measured using OCT and assessed by a central reader.

Time frame:
Baseline and Final/Early Termination Visit (up to 80 weeks)
Reported as:
Mean · percent change
Percent Change in Central Retinal Thickness in Each Eye From Baseline to the Final/Early Termination Visit.
percent changeMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Left eye (N = 107, 114, 122, 130)6.4 ± 20.674.5 ± 29.826.3 ± 19.755.2 ± 29.91
Right eye (N = 108, 113, 124, 129)7.7 ± 28.885.4 ± 34.839.9 ± 30.793.9 ± 33.34
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.451 · Mean difference: -2.3 · 95% CI -8.5 to 3.8The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.174 · Mean difference: -3.9 · 95% CI -9.7 to 1.8The mean difference between treatment groups with its 95% confidence interval is based on individual data from all eyes adjusted for correlated measurements within a subject in an analysis of variance (ANOVA) model.
SecondaryChange in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit

The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

Time frame:
Baseline and Final/Early Termination Visit (up 80 weeks)
Reported as:
Mean · units on a scale
Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit1.24 ± 10.6983.36 ± 11.731.00 ± 10.2252.79 ± 12.018
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.160 · Mean difference: 2.12 · 95% CI -0.84 to 5.08From ANOVA of change from baseline to final/early termination visit with treatment as a factor.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.205 · Mean difference: 1.77 · 95% CI -0.97 to 4.52From ANOVA of change from baseline to final/early termination visit with treatment and race (Japanese versus non-Japanese) as factors.
SecondaryChange in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit

The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 distance vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

Time frame:
Baseline and Final/Early Termination Visit (up 80 weeks)
Reported as:
Mean · units on a scale
Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit0.76 ± 16.2482.64 ± 17.1650.60 ± 15.9782.96 ± 17.121
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.401 · Mean difference: 1.88 · 95% CI -2.53 to 6.29From ANOVA of change from baseline to final/early termination visit with treatment as a factor.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.256 · Mean difference: 2.36 · 95% CI -1.73 to 6.45From ANOVA of change from baseline to final/early termination visit with treatment and race (Japanese versus non-Japanese) as factors.
SecondaryChange in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit

The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The near vision subscore is calculated from the answers to 3 near vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.

Time frame:
Baseline and Final/Early Termination Visit (up 80 weeks)
Reported as:
Mean · units on a scale
Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit3.98 ± 17.3973.88 ± 18.3023.73 ± 17.172.89 ± 50.503
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.967 · Mena difference: -0.10 · 95% CI -4.81 to 4.61From ANOVA of change from baseline to final/early termination visit with treatment as a factor.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.714 · Mean difference: -0.87 · 95% CI -5.53 to 3.79From ANOVA of change from baseline to final/early termination visit with treatment and race (Japanese versus non-Japanese) as factors.
SecondaryChange in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit

The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The ocular pain subscore is calculated form the answers to 2 eye pain questions and ranges from 0 to 100, where higher scores or increases in score indicate less pain.

Time frame:
Baseline and Final/Early Termination Visit (up 80 weeks)
Reported as:
Mean · units on a scale
Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit
units on a scaleMain Study: PlaceboMain Study: AdalimumabIntegrated Study (Main + Japan Sub-study): PlaceboIntegrated Study (Main + Japan Sub-study): Adalimumab
Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit2.87 ± 17.2333.42 ± 21.322.60 ± 17.3392.15 ± 21.689
Statistical analysis
  • Main Study: Placebo vs Main Study: Adalimumab · ANOVA · p = 0.830 · Mean difference: 0.56 · 95% CI -4.56 to 5.68From ANOVA of change from baseline to final/early termination visit with treatment as a factor.
  • Integrated Study (Main + Japan Sub-study): Placebo vs Integrated Study (Main + Japan Sub-study): Adalimumab · ANOVA · p = 0.842 · Mean difference: -0.49 · 95% CI -5.32 to 4.34From ANOVA of change from baseline to final/early termination visit with treatment and race (Japanese vs. non-Japanese) as factors.

Adverse events

Collected over From the first study drug administration until 70 days following the last study drug administration or until rollover into the extension study. Median duration of treatment was 147 days in the placebo arm and 245 days in the adalimumab arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—10/130 (7.7%)78/130 (60%)
Adalimumab—8/131 (6.1%)88/131 (67.2%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboAdalimumab
DEEP VEIN THROMBOSISVascular disorders2/1300/131
CHOROIDAL NEOVASCULARISATIONEye disorders1/1300/131
RETINAL DETACHMENTEye disorders1/1300/131
SUBRETINAL FLUIDEye disorders1/1300/131
MENINGITIS ASEPTICInfections and infestations1/1300/131
TONSILLITISInfections and infestations1/1300/131
HUMERUS FRACTUREInjury, poisoning and procedural complications1/1300/131
ARTHRITISMusculoskeletal and connective tissue disorders1/1300/131
OSTEONECROSISMusculoskeletal and connective tissue disorders1/1300/131
HYPERTENSIVE CRISISVascular disorders1/1300/131
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboAdalimumab
ARTHRALGIAMusculoskeletal and connective tissue disorders12/13028/131
NASOPHARYNGITISInfections and infestations20/13023/131
HEADACHENervous system disorders17/13017/131
FATIGUEGeneral disorders9/13014/131
URINARY TRACT INFECTIONInfections and infestations11/13013/131
COUGHRespiratory, thoracic and mediastinal disorders6/13011/131
VISUAL ACUITY REDUCEDEye disorders10/1306/131
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/13010/131
BACK PAINMusculoskeletal and connective tissue disorders7/13010/131
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders3/13010/131

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAdalimumabTotal
Mean43.22 ± 14.02643.18 ± 12.71943.20 ± 13.360
Age, Customized
Age, Customized(participants)PlaceboAdalimumabTotal
< 65 years121125246
≥ 65 years9615
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumabTotal
Female8375158
Male4756103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAdalimumabTotal
White9696192
Black8614
Asian191938
American Indian/Alaskan Native101
Native Hawaiian or Other Pacific Islander000
Other5914
Multi-Race112
Type of Uveitis
Type of Uveitis(participants)PlaceboAdalimumabTotal
Intermediate301747
Posterior364177
Panuveitis6371134
Intermediate/Posterior123
Diagnosis
Diagnosis(participants)PlaceboAdalimumabTotal
Idiopathic453378
Birdshot Choroidopathy161531
Multifocal Choroiditis and Panuveitis257
Vogt Koyanagi Harada303464
Sarcoid202242
Behcet's71017
Other101222
Eye Affected
Eye Affected(participants)PlaceboAdalimumabTotal
Left336
Right527
Both122126248
History of Infectious Uveitis
History of Infectious Uveitis(participants)PlaceboAdalimumabTotal
Yes000
No130131261

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brezin AP. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Erratum In: Lancet. 2016 Sep 17;388(10050):1160. doi: 10.1016/S0140-6736(16)31538-0. PubMed 27542302 ↗
  • Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017 Jun 1;135(6):511-518. doi: 10.1001/jamaophthalmol.2017.0603. PubMed 28426849 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2010
First posted
May 17, 2010
Start
Aug 2010
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 21, 2016
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01124838
Responsible party
Sponsor
First posted
May 17, 2010
Start date
Aug 2010
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 21, 2016
Last update
Jul 7, 2021

Study contacts

Andy Payne
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion